Paroxetine
( DrugBank: Paroxetine / KEGG DRUG: Paroxetine hydrochloride hemihydrate, Paroxetine, Paroxetine hydrochloride, Paroxetine mesylate )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 3 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 8 |
| 85 | Idiopathic interstitial pneumonia | 1 |
6. Parkinson disease
Clinical trials : 2,817 / Drugs : 2,606 - (DrugBank : 348) / Drug target genes : 185 - Drug target pathways : 205
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,898 / Drugs : 2,785 - (DrugBank : 360) / Drug target genes : 265 - Drug target pathways : 239
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
46. Malignant rheumatoid arthritis
Clinical trials : 4,743 / Drugs : 3,042 - (DrugBank : 389) / Drug target genes : 205 - Drug target pathways : 253
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
85. Idiopathic interstitial pneumonia
Clinical trials : 768 / Drugs : 558 - (DrugBank : 126) / Drug target genes : 103 - Drug target pathways : 214
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|